The DOI matches its Crossref record; 127 of the 127 references it cites were found in a registry or an index.
Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status
Open accessAbstract
The efficacy of standard antidepressants is limited for many patients with mood disorders such as major depressive disorder (MDD) and bipolar depression, underscoring the urgent need to develop novel therapeutics. Both clinical and preclinical studies have implicated glutamatergic system dysfunction in the pathophysiology of mood disorders. In particular, rapid reductions in depressive symptoms have been observed in response to subanesthetic doses of the glutamatergic modulator racemic (R,S)-ketamine in individuals with mood disorders. These results have prompted investigation into other glutamatergic modulators for depression, both as monotherapy and adjunctively. Several glutamate receptor-modulating agents have been tested in proof-of-concept studies for mood disorders. This manuscript gives a brief overview of the glutamate system and its relevance to rapid antidepressant response and discusses the existing clinical evidence for glutamate receptor-modulating agents, including (1) broad glutamatergic modulators ((R,S)-ketamine, esketamine, (R)-ketamine, (2R,6R)-hydroxynorketamine [HNK], dextromethorphan, Nuedexta [a combination of dextromethorphan and quinidine], deudextromethorphan [AVP-786], axsome [AXS-05], dextromethadone [REL-1017], nitrous oxide, AZD6765, CLE100, AGN-241751); (2) glycine site modulators (D-cycloserine [DCS], NRX-101, rapastinel [GLYX-13], apimostinel [NRX-1074], sarcosine, 4-chlorokynurenine [4-Cl-KYN/AV-101]); (3) subunit (NR2B)-specific N-methyl-D-aspartate (NMDA) receptor antagonists (eliprodil [EVT-101], traxoprodil [CP-101,606], rislenemdaz [MK-0657/CERC-301]); (4) metabotropic glutamate receptor (mGluR) modulators (basimglurant, AZD2066, RG1578, TS-161); and (5) mammalian target of rapamycin complex 1 (mTORC1) activators (NV-5138). Many of these agents are still in the preliminary stages of development. Furthermore, to date, most have demonstrated relatively modest effects compared with (R,S)-ketamine and esketamine, though some have shown more favorable characteristics. Of these novel agents, the most promising, and the ones for which the most evidence exists, appear to be those targeting ionotropic glutamate receptors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Glycine site modulators such as GLYX-13, apimostinel, and 4-Chlorokynurenine (AV-101) experienced similar difficulties [168]”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [168]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Self-citationmTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881 · cited 2×
“As noted above, mTORC1 has been implicated as a downstream pathway connecting glutamate modulation with the induction of neuroplastic processes [32].”
BackgroundSteroid hormone metabolites are barbiturate-like modulators of the GABA receptor
Majewska, M. D., Harrison, N. L., Schwartz, R. D., Barker, J. L., & Paul, S. M. (1986) · Science · doi:10.1126/science.2422758 · Cited by 2,225
Moghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793 · cited 1×
“Disinhibition of the pyramidal neuron would thus result in a transient, but significant, increase of extracellular glutamate—sometimes referred to as a ‘glutamate burst’— which is thought to be critical for antidepressant response [28], though it remains unclear how the glutamate burst leads to antidepressant effects.”
BackgroundNMDAR inhibition-independent antidepressant actions of ketamine metabolites
Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., Alkondon, M., Yuan, P., Pribut, H. J., Singh, N. S., et al. (2016) · Nature · doi:10.1038/nature17998 · Cited by 1,609
Self-citationMurrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Green, C. E., Perez, A. M., Iqbal, S., Pillemer, S., Foulkes, A., Shah, A., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13030392 · Cited by 1,205 · cited 1×
“Since then, most of the placebo-controlled, double-blind, randomized trials examining this agent have demonstrated the antidepressant efficacy of subanesthetic-dose (R,S)-ketamine in individuals with TRD [8, 40] as well as bipolar depression [41, 42].”
BackgroundMechanisms of ketamine action as an antidepressant
Zanos, P., & Gould, T. D. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.255 · Cited by 1,127 · cited 1×
“Theories posited to explain (R,S)-ketamine’s mechanism of action include (i) inhibition of NMDA receptor-mediated transmission at the synapse; (ii) direct inhibition of extrasynaptic NMDA receptors; (iii) inhibition of NMDA receptor-dependent bursting activity in the lateral habenula; and (iv) inhibition of NMDA recep…”
BackgroundPlacebo Response in Studies of Major Depression: Variable, Substantial, and Growing
Walsh, B. T., Seidman, S. N., Sysko, R., & Gould, M. (2002) · JAMA · doi:10.1001/jama.287.14.1840 · Cited by 1,109 · cited 1×
“In addition, placebo response rates are highly variable [132], difficult to predict, and can hinder drug development.”
Background
Research works printed but not linked: 3
- NeuroRx. NeuroRx: Phase 3 drug for suicidal bipolar depression to present at BIO CEO conference. February 10, 2020. 2020. https://www.prnewswire.com/news-releases/neurorx-phase-3-drug-for-suicidal-bipolar-depression-to-present-at-bio-ceo-conference-301001882.html. Accessed 12 Aug 2020.
- Paterson B, Fraser H, Wang C, Marcus R. A randomized, double-blind, placebo-controlled, sequential parallel study of CERC-301 in the adjunctive treatment of subjects with severe depression and recent active suicidal ideation despite antidepressant treatment. National Network of Depression Centers Annual Conference; 2015 November 5-6; Ann Arbor, Michigan; 2015. http://c.eqcdn.com/_2a1b537df6a6e1398b6806c9b30635ad/cerecor/db/322/603/file/Poster+-+Study+Clin301-201_FINAL.pdf. Accessed 12 June 2020.
- Sage Therapeutics. Sage announces pivotal Phase 3 trial status for SAGE-217 in major depressive disorder and postpartum depression based on FDA breakthrough therapy meeting. 2018. https://investor.sagerx.com/news-releases/news-release-details/sage-announces-pivotal-phase-3-trial-status-sage-217-major. Accessed 12 June 2020.
Cited by
New and emerging approaches to treat psychiatric disorders
Scangos, K. W., State, M. W., Miller, A. H., Baker, J. T., & Williams, L. M. (2023) · Nature Medicine · doi:10.1038/s41591-022-02197-0 · Cited by 177
Ketamine Treatment for Depression: A Review
Yavi, M., Lee, H., Henter, I. D., Park, L. T., & Zarate, C. A. (2022) · Discover Mental Health · doi:10.1007/s44192-022-00012-3 · Cited by 161
Self-citationGut-Brain Axis: Role of Microbiome, Metabolomics, Hormones, and Stress in Mental Health Disorders
Verma, A., Inslicht, S. S., & Bhargava, A. (2024) · Cells · doi:10.3390/cells13171436 · Cited by 159
Novel drug developmental strategies for treatment‐resistant depression
Borbély, É., Simon, M., Fuchs, E., Wiborg, O., Czéh, B., & Helyes, Z. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15753 · Cited by 132
Correll, C. U., Solmi, M., Cortese, S., Fava, M., Højlund, M., KRAEMER, H. C., McIntyre, R. S., Pine, D. S., Schneider, L. S. S., & Kane, J. M. (2023) · World Psychiatry · doi:10.1002/wps.21056 · Cited by 120
Metadata
- Authors
- Henter, I. D., Park, L. T., & Zarate, C. A.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Zarate, Carlos A.
- Venue
- CNS Drugs
- Published
- 2021-04-26
- Volume
- 35
- Issue
- 5
- Pages
- 527-543
- ISSN
- 1172-7047 (ISSN-L)
- 1179-1934
- PMC
- PMC8201267
- OpenAlex
- W3157093408
- Cited by
- 142
- References
- 127
- Citations by year
- 2026: 19 · 2025: 20 · 2024: 34 · 2023: 28 · 2022: 29 · 2021: 12
- FWCI
- 3.29
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- CNS Drugs (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Mental Health (ZIAMH002857)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- mood disorders, major depressive disorder, bipolar depression, ketamine, esketamine, hydroxynorketamine, dextromethorphan, D-cycloserine, NMDA receptor antagonists, rapid antidepressant response, antidepressant resistance
- MeSH terms
- Animals, Antidepressive Agents, Bipolar Disorder, Major Depressive Disorder, Humans, Receptors, Glutamate, Excitatory Amino Acid Agents, Glutamic Acid, Mood Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status. https://app.cochat.ai/papers/10.1007/s40263-021-00816-x
- The paper
- Henter, I. D., Park, L. T., & Zarate, C. A. (2021). Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status. CNS Drugs. https://doi.org/10.1007/s40263-021-00816-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.